| Abstract text: |
GELA LNH 98.5 study comparing R-CHOP with CHOP, established R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) as the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL). GELA LNH 98.5 study data after 2, 5 and 7 years of follow-up has previously been published. An overview of the data after 10 year follow up shows that the benefit observed in terms of EFS, DFS, PFS and OS after 2, 5 and 7 years of follow-up is still significant at 10 years. R-CHOP as first line DLBCL treatment improves patients long-term outcomes. |
